588 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Tuesday’s Close
LLY Eli Lilly and Company $105.71 $113.53B N/A
Article Searches
Pharma Stock Roundup: Is Sanofi Buying Flexion? Pfizer, Merck KGaA Drug Approved http://www.zacks.com/stock/news/253983/pharma-stock-roundup-is-sanofi-buying-flexion-pfizer-merck-kgaa-drug-approved?cid=CS-ZC-FT-253983 Mar 24, 2017 - This week's highlights include rumors regarding Sanofi (SNY) acquiring Flexion, accelerated FDA approval for a Pfizer/Merck KGaA drug and drug pricing.
AstraZeneca Stock Rising in '17: What's Working in its Favor? http://www.zacks.com/stock/news/253879/astrazeneca-stock-rising-in-17-whats-working-in-its-favor?cid=CS-ZC-FT-253879 Mar 23, 2017 - Shares of London-based pharma giant, AstraZeneca plc (AZN) have risen 13.4% this year so far, while the Zacks classified Large-Cap Pharma industry increased 6.4%.
Merck Closes Acquisition of Controlling Stake in Vallee S.A http://www.zacks.com/stock/news/253862/merck-closes-acquisition-of-controlling-stake-in-vallee-sa?cid=CS-ZC-FT-253862 Mar 23, 2017 - Merck & Co., Inc. (MRK) has completed the previously announced acquisition of a controlling stake in Vallee S.A., a leading privately held producer of animal health products in Brazil.
Novartis' Acute Heart Failure Drug Fails in Late-Stage Study http://www.zacks.com/stock/news/253764/novartis-acute-heart-failure-drug-fails-in-late-stage-study?cid=CS-ZC-FT-253764 Mar 22, 2017 - Novartis AG (NVS) recently suffered a setback on the announcement of disappointing data from a phase III study, RELAX-AHF-2, on pipeline candidate serelaxin (RLX030).
Lilly's Breast Cancer Combo Drug Phase III Results Positive http://www.zacks.com/stock/news/253465/lillys-breast-cancer-combo-drug-phase-iii-results-positive?cid=CS-ZC-FT-253465 Mar 21, 2017 - Eli Lilly and Company (LLY) recently announced that a phase III combination study evaluating its pipeline candidate abemaciclib in advanced breast cancer, met the primary endpoint of progression-free survival (PFS).
Novartis (NVS) Announces Positive Data on Heart Failure Drug http://www.zacks.com/stock/news/253425/novartis-nvs-announces-positive-data-on-heart-failure-drug?cid=CS-ZC-FT-253425 Mar 20, 2017 - Novartis AG (NVS) recently announced results of a new post-hoc analysis from the PARADIGM-HF study on heart failure drug Entresto.
What are Sanofi's (SNY) Strengths and Challenges in 2017? http://www.zacks.com/stock/news/253198/what-are-sanofis-sny-strengths-and-challenges-in-2017?cid=CS-ZC-FT-253198 Mar 17, 2017 - We issued an updated research report on Sanofi (SNY) on Mar 16, 2017.
Novo Nordisk's Diabetes Unit Strong; Generic Pressure Stays http://www.zacks.com/stock/news/252549/novo-nordisks-diabetes-unit-strong-generic-pressure-stays?cid=CS-ZC-FT-252549 Mar 13, 2017 - We issued an updated research report on Novo Nordisk (NVO) on Mar 9, 2017.
How Incyte Stock Became a Bull Market Star for Biotech Investors http://www.zacks.com/stock/news/252365/how-incyte-stock-became-a-bull-market-star-for-biotech-investors?cid=CS-ZC-FT-252365 Mar 10, 2017 - Incyte (INCY) tops the list of stocks that enjoyed a stupendous run in the last 8 years.
Trump Tweet on Drug Pricing Hits Biotech and Pharma ETFs http://www.zacks.com/stock/news/252108/trump-tweet-on-drug-pricing-hits-biotech-and-pharma-etfs?cid=CS-ZC-FT-252108 Mar 08, 2017 - President Donald Trump March 7 tweet on increasing competition and lowering drug prices sent fresh shockwaves across the industry.

Pages: 1...50515253545556575859

<<<Page 55>